Hyperforin as a possible antidepressant component of hypericum extracts

Life Sciences

Volumn 63, Issue 6, 1998, Pages 499-510

  Chatterjee, S S ^a   Bhattacharya, S K ^b   Wonnemann, M ^c   Singer, A ^c   Muller W E ^c  

^a DR WILLMAR SCHWABE GMBH AND CO KG   (Germany)

^b BANARAS HINDU UNIVERSITY   (India)

^c GOETHE UNIVERSITY   (Germany)

Author keywords

Antidepressant activity; Hyperforin; Hypericum extract

Indexed keywords

ANTIDEPRESSANT AGENT; DOPAMINE UPTAKE INHIBITOR; HYPERFORIN; HYPERICUM PERFORATUM EXTRACT; NORADRENALIN UPTAKE INHIBITOR; PHLOROGLUCINOL DERIVATIVE; SEROTONIN UPTAKE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DEPRESSION; HELPLESSNESS; HYPERICUM PERFORATUM; MALE; NEUROPHARMACOLOGY; NONHUMAN; ORAL DRUG ADMINISTRATION; PSYCHOPHARMACOLOGY; RAT;

ANIMALIA; HYPERICUM; HYPERICUM PERFORATUM; SAINT JOHNS WORT;

EID: 0032479206     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0024-3205(98)00299-9     Document Type: Article

References (46)

1. 1. M.J. LOHSE, B. MÜLLER-OERLINGHAUSEN, Arzneiverordnungs-Report '95. Aktuelle Daten, Kosten, Trends und Kommentare, U. Schwabe and D. Paffrath (eds.), 360-377, Gustav Fischer, Stuttgart (1995).
2. 2. H.P. VOLZ, Pharmacopsychiatry. 30 72-76 (1997).
3. 3. K. LINDE, G. RAMIREZ, C.D. MULROW, A. PAULS, W. WEIDENHAMMER, D. MELCHART, BMJ 313 253-258 (1996).
4. 4. D. WHEATLEY, Pharmacopsychiatry 30 77-80 (1997).
5. 5. H. WOELK, G. BURKARD, J. GRÜNWALD, J. Geriatr. Psychiatry Neurol. 7 (Suppl. 1) S34-S38 (1994).
6. 6. P.A.G.M. DE SMET, W.A. NOLEN, BMJ 313 241-242 (1996).
7. 7. E.U. VORBACH, K.H. ARNOLDT, W.-D. HÜBNER, Pharmacopsychiatry 30 81-85 (1997).
8. 8. M. ROLLI, C. SCHÄFER, W.E. MÜLLER, Pharmacopsychiatry 28 207 (1995).
9. 9. S. PEROVIC, W.E.G. MÜLLER, Arzneimittelforsch. 45 1145-1148 (1995).
10. 10. W.E MÜLLER, M. ROLLI, C. SCHÄFER, U. HAFNER, Pharmacopsychiatry 30 102-107 (1997).
11. 11. H. WINTERHOFF, V. BUTTERWECK, A. NAHRSTEDT, H.G. GUMBINGER, V. SCHULZ, S. ERPING, F. BOSSHAMMER, A WIELIGMANN, Phytopharmaka in Forschung und klinischer Anwendung, D. Loew and M. Rietbrock (eds.), 39-56, Steinkopff-Verlag, Darmstadt (1995).
12. 12. V. BUTTERWECK, A WALL, U. LIEFLÄNDER-WULF, H. WINTERHOFF, A. NAHRSTEDT, Pharmacopsychiatry 30 117-124 (1997).
13. 13. Y. ÖZTÜRK, S. AYDIN, R. BEIS, K.H.C. BASER, H. BERGEROGLU, Phytomedicine 3 139-146 (1996).
14. 14. H. SCHÜTT, V. SCHULZ, Hagers Handbuch der Pharmazeutischen Praxis, 5th ed., vol. 5, R. Hänsel, K. Keller, H. Rimpler and G. Schneider (eds.), 474-495, Springer-Verlag, Berlin (1993).
15. 15. COMMISSION E OF THE GERMAN FEDERAL PUBLIC HEALTH DEPARTMENT, Monograph "Hyperici herba, Johanniskraut" (1984, correction 1989).
16. 16. S.S. CHATTERJEE, E. KOCH, M. NÖLDNER, A. BIBER, C. ERDELMEIER, Phytomedicine 3 (Suppl. 1) 106 (1996).
17. 17. E. BOMBARDELLI, P. MORAZZONI, Fitoterapia LXVI 43-67 (1995)
18. 18. R.D. PORSOLT, M. LE PICHON, M. JALFRE, Nature 266 730-731 (1977).
19. 19. M.E.P. SELIGMAN, G. BEAGLEY, J. Comp. Physiol. Psychol. 88 534-541 (1975).
20. 20. M.E.P. SELIGMAN, S.F. MAJER, J. Exp. Psychol. 74 1-9 (1967).
21. 21. W.F. YOUNG, E.R, LAWS, F.W. SHARBROUGH, R.M. WEINSHIELKOUM, Arch. Gen. Psychiatry 43 604-609 (1986).
22. 22. R. MARCUS, E. PERITZ, K.B. GABRIE, Biometrika 63 655-660 (1976).
23. 23. A.R. JONKHEEREE, Biometrika 41 133-145 (1954).
24. 24. P. WILLNER, Psychopharmacology 83 1-45 (1984).
25. 25. P. WILLNER, Anxiety, depression and mania Animal models. Psychiatric Disorders, P. Soubrie, (ed.), 71-99, Karger, Basel (1991).
26. 26. C. GAMBARANA, O. GHIGLIERI, D. GIACHETTI, I. TADDEI, Phytomedicine 3 (Suppl. 1) 264 (1996).
27. 27. NIH CONSENSUS DEVELOPMENT PANEL ON DEPRESSION IN LATE LIFE, JAMA 268 1018-1024 (1992).
28. 28. L. EISENBERG, New Engl. J. Med. 326 1080-1084 (1992).
29. 29. S.J. KEITH S.M. MATTHEWS, Psychopharmacol. Bull. 29 427-430 (1993).
30. 30. H.J. MÖLLER H.P. VOLZ, Drugs 52 625-638 (1996).
31. 31. C.L.E. BROEKKAMP, D. LEYSEN, B.W.M.M PEETERS, R.M. PINDER, J. Med. Chem. 38 4615-4633 (1995).
32. 32. R. KUHN, Am. J. Psychiatry 115 459-464 (1958).
33. 33. W.Z. POLTER, H.K. MANJI, O.T. OSMAN, M.V. RUDORFER, New Prospects in Psychiatry: the bio-clinical interface, P.J. Macher and M.A. Crocq (eds.), 113-129, Elsevier, New York (1992).
34. 34. J.M. PEZZUTO, Biochem. Pharmacol. 53 121-133 (1997).
35. 35. A.D. KINGHORN, M.F. BALANDRIN, ACS symposium series No. 534, 2-12, American Chemical Society Books, Washington (1993).
36. 36. J.A. DUKE, Psychopharmacol. Bull. 31 177-184 (1995).
37. 37. J. COTT, Psychopharmacol. Bull. 31 745-751 (1995).
38. 38. O. SUZUKI, Y. KATSUMATA, M. OYA, S. BLADT, H. WAGNER, Planta Medica 50 272-274 (1984).
39. 39. S.N. OKPANYI, M.L. WEISCHER, Arzneimittelforschung 37 10-13 (1987).
40. 39. G. RÜCKER, D. MANN, R. HARTMANN, U. BONSELS, Arch. Pharm. (Weinheim) 328 725-730 (1995).
41. 40. S. BALDT, H. WAGNER, Nervenheilkunde 12 349-352 (1993).
42. 41. J. COTT, Psychopharmacol. Bull. 31 131-137 (1995).
43. 42. B. SPARENBERG, L. DEMISCH, J. HÖLZL, Pharm. Ztg. Wiss. 138 50-54 (1993).
44. 43. L. DEMISCH, J. HÖLZL, B. GOLLNIK, P. KACZMARZYK, Pharmacopsychiatry 22 194 (1989).
45. 44. M. WONNEMANN, C. SCHÄFER, W.E. MÜLLER, Pharmacopsychiatry 30 237 (1997).
46. 45. W.B. JONAS, Nature Med. 3 824-827 (1997).